SARS-CoV-2/COVID-19: Empfehlungen zu Diagnostik und Therapie

Berthold Bein; Martin Bachmann; Susanne Huggett; Petra Wegermann

doi:10.1055/a-1155-2131

Krankenhaushygiene up2date, Table of Contents

Krankenhaushygiene up2date 2020; 15(02): 109-118
DOI: 10.1055/a-1155-2131

Meldungen und Meinungen

SARS-CoV-2/COVID-19: Empfehlungen zu Diagnostik und Therapie

Authors

Berthold Bein
Martin Bachmann
Susanne Huggett
Petra Wegermann

Abstract

All articles of this category

Der Übersichtsartikel ist als praktische Handreichung für alle gedacht, die COVID-19-Patienten behandeln bzw. in nächster Zeit behandeln werden, und fasst das derzeit verfügbare Wissen zu Diagnostik und Therapie zusammen. Zusätzlich werden auch neue und experimentelle Therapien bewertet, soweit dazu zumindest Einzelfallberichte vorliegen.

Full Text

References

Literatur
1 Johns Hopkins Coronavirus Resource Center. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Im Internet: https://coronavirus.jhu.edu/map.html Stand: 28.03.2020
2 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 102433
3 Andersen KG, Rambaut A, Lipkin WI. et al. The proximal origin of SARS-CoV-2. Nat Med 2020;
4 Adhikari SP, Meng S, Wu Y-J. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9: 29
5 Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan. JAMA 2020;
6 Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020; 48: 155-163
7 Wu JT, Leung K, Bushman M. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020;
8 Cruz A, Zeichner S. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics 2020;
9 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020;
10 Center of Disease Control. Healthcare Professionals: frequently asked questions and answers. CDC. Im Internet: https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html Stand: 28.03.2020
11 Bao L, Deng W, Gao H. et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. Cold Spring Harbor Laboratory; 2020
12 Zou L, Ruan F, Huang M. et al. SARS-CoV-2 Viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-1179
13 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;
14 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061
15 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
16 Guan W, Ni Z, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;
17 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062 doi:10.1016/S0140-6736(20)30566-3
18 Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;
19 Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome. JAMA 2018; 319: 698
20 AWMF. S3-Leitlinie Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz, 1. Aufl, Langversion. Stand 04.12.2017. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/001-021l_S3_Invasive_Beatmung_2017-12.pdf Stand. 28.03.2020
21 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;
22 Mehta P, McAuley DF, Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-1034 doi:10.1016/S0140-6736(20)30628-0
23 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513
24 Reusken CBEM, Broberg EK, Haagmans B. et al. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Eurosurveillance 2020;
25 Robert Koch-Institut – RKI. Coronavirus SARS-CoV-2 – Hinweise zur Testung von Patienten auf Infektion mit dem neuartigen Coronavirus SARS-CoV-2. Im Internet: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Vorl_Testung_nCoV.html Stand: 28.03.2020
26 Robert Koch-Institut – RKI. Coronavirus SARS-CoV-2 – Optionen zum Management von Kontaktpersonen unter medizinischem Personal bei Personalmangel. Im Internet: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/HCW.html Stand: 28.03.2020
27 Anonymous COVID-19: protecting health-care workers. Lancet 2020; 395: 922 doi:10.1016/S2213-2600(20)30066-7
28 AWMF online. Empfehlungen Krankenhaushygiene: Hygieneanforderungen respiratorisch übertragbare Infektions-Erkrankungen. Im Internet: https://www.awmf.org/fileadmin/user_upload/Leitlinien/029_AWMF-AK_Krankenhaus-_und_Praxishygiene/HTML-Dateien/029-032l_S1_Hygiene_respiratorisch-uebertragbare_Infektionserkrankungen_2016-01.html Stand: 28.03.2020
29 Robert Koch-Institut – RKI. Infektionsprävention im Rahmen der Pflege und Behandlung von Patienten mit übertragbaren Krankheiten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2015; 58: 1151-1170
30 Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020;
31 Radonovich LJ, Simberkoff MS, Bessesen MT. et al. N95 Respirators vs. Medical Masks for Preventing Influenza Among Health Care Personnel. JAMA 2019; 322: 824
32 Sektion 2 Endoskopie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Empfehlung. Im Internet: https://pneumologie.de/fileadmin/user_upload/Aktuelles/2020-03_DGP-Empfehlung_Broncho_Covid19.pdf Stand: 04.04.2020
33 Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome. JAMA 2018; 319: 698
34 Oczkowski S, Levy MM, Derde L. et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Authors Intensive Care Medicine (ICM) and Critical Care Medicine (CCM). Intensive Care Med 2020;
35 Kluge S, Janssens U, Welte T. et al. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19. Med Klin Intensivmed Notfallmed 2020;
36 LeTourneau JL, Pinney J, Phillips CR. Extravascular lung water predicts progression to acute lung injury in patients with increased risk. Crit Care Med 2012; 40: 847-854
37 Bein B, Renner J. Best practice & research clinical anaesthesiology: Advances in haemodynamic monitoring for the perioperative patient. Best Pract Res Clin Anaesthesiol 2019; 33: 139-153
38 Müller C. DAZ online. WHO rät doch nicht von Ibuprofen ab: Ibuprofen und COVID-19: WHO rudert zurück. Im Internet: https://www.deutsche-apotheker-zeitung.de/news/artikel/2020/03/19/ibuprofen-und-covid-19-who-rudert-zurueck Stand: 28.03.2020
39 Cao B, Wang Y, Wen D. et al. A Trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;
40 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92: 479-490
41 Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762
42 Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-73
43 Cortegiani A, Ingoglia G, Ippolito M. et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;
44 Kalil AC. Treating COVID-19 – Off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020;
45 Ramanathan K, Antognini D, Combes A. et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020;
46 Peek GJ, Mugford M, Tiruvoipati R. et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351-1363
47 Combes A, Hajage D, Capellier G. et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med 2018; 378: 1965-1975
48 Ruan Q, Yang K, Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;
49 Kogelmann K, Jarczak D, Scheller M. et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21: 74